title: Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.
abstract: The aims of the present study were to characterize the relationship between plasma racemic methadone and its enantiomers' concentrations with respect to their pharmacodynamic effects and to investigate the influence of potential covariates on the pharmacodynamic parameters in patients on methadone maintenance treatment (MMT). Eighty-eight regular subjects at the Sheffield Care Trust Substance Misuse Services were studied. Samples of blood and urine were collected before the daily dose of methadone. Blood samples were taken up to 5 hours after dose. Total plasma concentrations of (RS)-methadone and total and unbound plasma concentrations of both enantiomers were measured by liquid chromatography-mass spectrometry. The Total Mood Disturbance Score (TMDS), the Objective Opioid Withdrawal Scale (OOWS), and the Subjective Opioid Withdrawal Scale (SOWS) were used as measures of mood and withdrawal. Population pharmacokinetic/pharmacodynamic analysis and subsequent multiple regression analysis were used to determine the factors influencing the pharmacodynamic effects of methadone. Significant decreases (P ≤ 0.04) were observed in the scores for the TMDS, SOWS, and OOWS for 5 hours after methadone dosage. The TMDS had returned to baseline by 10 hours after dose (P = 0.98), at which time the SOWS remained significantly below baseline (P = 0.001). Multiple regression analysis revealed that 33% of the overall variation in unbound (R)-methadone EC50 was explained by 3 variables, namely CYP3A activity (9%), age (16%), and sex (8%). Age also accounted for 8% and 9% of the variation in total (rac)- and (R)-methadone EC50. The present study has confirmed that the duration of mood change in the present study was shorter than the effect of methadone in stabilizing withdrawal symptoms. Thus, it is likely that a once-daily dose of methadone, albeit effective for preventing withdrawal, may not be sufficient to improve mood in some patients. Finally, it was established that CYP3A activity, years of dependent use, sex, and age are major determinants of methadone EC50 with respect to TMDS.
authors.affiliation: Academic Unit of Clinical Pharmacology, University of Sheffield, Sheffield, UK. mr.shiran@gmail.com
authors.forename: Mohammad-Reza
authors.initials: MR
authors.lastname: Shiran
authors.forename: Martin S
authors.initials: MS
authors.lastname: Lennard
authors.forename: Mohammad-Zafar
authors.initials: MZ
authors.lastname: Iqbal
authors.forename: Olawale
authors.initials: O
authors.lastname: Lagundoye
authors.forename: Nicholas
authors.initials: N
authors.lastname: Seivewright
authors.forename: Geoffrey T
authors.initials: GT
authors.lastname: Tucker
authors.forename: Amin
authors.initials: A
authors.lastname: Rostami-Hodjegan
mesh_terms: D000339:Affect / Q000187:drug effects; D000367:Age Factors; D002853:Chromatography, Liquid; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008691:Methadone / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D008954:Models, Biological; D009294:Narcotics / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D058850:Opiate Substitution Treatment / Q000379:methods; D012044:Regression Analysis; D012737:Sex Factors; D013237:Stereoisomerism; D016320:Substance Abuse Treatment Centers; D013375:Substance Withdrawal Syndrome
chemical_list: D009294:Narcotics; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D008691:Methadone